• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Adare Pharma Solutions

    Reed-Lane

    test company saurabh
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    test company saurabh

    Alcami

    Baxter BioPharma Solutions

    PCI Pharma Services

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Reducing Development-to-Production Timescales for COVID-19 Vaccine

    The challenges moving from regulatory approval to full production and how they can be addressed at each step in the manufacturing process.

    Reducing Development-to-Production Timescales for COVID-19 Vaccine
    Related CONTENT
    • Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact
    • GRAM, J&J Enter COVID-19 Vax Manufacturing Pact
    • J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax
    • Hovione to Support Manufacture of Remdesivir for COVID-19
    • ARCA Submits IND for AB201 in COVID-19
    Kristin Brooks, Contract Pharma06.15.20
    The need for vaccines and treatments to address the COVID-19 pandemic has the industry working under extremely abbreviated timelines. What would normally take the better part of a decade is being expedited at an unprecedented pace.

    Significantly reducing development-to-production timescales and enabling faster delivery of critical products is not without its challenges. The safe, efficient and rapid delivery of vaccines will require more efficient production and testing capabilities, along with facilitating a strengthened supply chain.

    Cynthia Pussinen, vice president and general manager, Life Sciences, Honeywell Process Solutions discusses the challenges associated with moving from regulatory approval to full production, and walks us through how they can be addressed at each step in the manufacturing process. –KB


    Contract Pharma: What are the hurdles in moving from regulatory approval to full production of a vaccine?

    Cynthia Pussinen: In an effort to optimally manage risk levels and resources, life sciences companies who are engaged in the discovery, development and commercialization of a new medical therapy have historically waited until the point in time at which confidence in successful outcomes, including safety, efficacy, ability to manufacture in a reproducible and consistent manner and ultimately regulatory approval is high.  

    In today’s world, there is often an immediate need for a vaccine or therapy. In the past, many life sciences companies have held off on making investments in facilities, infrastructure and materials to produce sufficient quantities of a medical therapy until late stage clinical studies were conducted with a commercial quantity scale up starting during the registration process.

    Challenges associated with moving from regulatory approval to full production of a vaccine are focused on speed to deliver an effective vaccine, including:
    1) balancing the need to urgently provide as much supply of a vaccine to the world as quickly and safely as possible once clinical trials have proven to be successful while investing in facilities and infrastructure earlier than has been seen historically
    2) ensuring a fully functional supply chain and distribution network is in place
    3) delivering a scalable manufacturing process, as vaccines are more technically complex to produce compared to a chemically synthesized, small molecule-based medicine.

    Contract Pharma: How can this process be safely expedited?

    Cynthia Pussinen: The process of delivering a vaccine to the public can be expedited through a variety of actions including repurposing existing facilities for use in commercial production, preparing commercial manufacturing facilities for production in parallel with early phase clinical studies - which involves increased risk if the vaccine in development doesn’t show safety or efficacy, working with the FDA or local regulatory bodies to schedule a facility pre-approval inspection early, understanding and requesting expedited regulatory pathways with the FDA including emergency use authorization.  

    Preparing your Good Manufacturing Process (GMP) compliant commercial facility for production will include:
    1) procuring and configuring the necessary equipment for your scaled up upstream and downstream processes as well as integrating the systems used to manufacture including Manufacturing Execution System (MES), Quality Management System (QMS), and (Supply Chain Management) SCM systems
    2) conducting Installation Qualification (IQ)/ Operational Qualification (OQ)/Performance Qualification (PQ) of the equipment, implementing upon a validation master plan and associated protocols
    3) readiness of testing labs to support scaled up production – starting activities earlier than would have been done in the past and parallel processing of efforts is a must do.  

    A key aspect of preparing for commercial production, and accelerating pathways is securing the supply chain and distribution networks; eliminating sources of vulnerability and having redundancy to ensure appropriate quantities of the various components used across expanded supply chain to include raw starting materials, cells banks, manufacturing materials, purification and testing, and buffers is required. Refrigerated storage facilities, necessary temperature-controlled logistics, shipping containers and vehicles will be required to move product around the world at unprecedented speed. Acting on building stock of needed supplies, components and logistics earlier than has been done in the past will facilitate speeding up the delivery to the patient once regulatory approval is granted.  

    Once a successful clinical outcome is achieved, collaboration and partnership across governments, industry and the medical communities along with comprehensive planning will be required, along with solid execution in manufacturing and distribution to supply a global solution to avoid pockets of unprotected populations in the process.

    Contract Pharma: What are some of the process requirement challenges?

    Cynthia Pussinen: In vaccines, the product is the process and therefore ensuring a well-controlled and highly consistent manufacturing process, with stringent oversight and data collection, is all the more critical. Quality of design, quality assurance and quality control testing for release of the product is more complex given that production of vaccines involves a biological process. Process development and optimizing your manufacturing process, including using the most productive host cell line available, while limiting sources of variability will help to ensure product batch to batch consistency.

    Contract Pharma: How can technology be leveraged to help overcome these challenges?

    Cynthia Pussinen: The use of automation and controls technologies include; robotics, distributed control systems and batch production technology, packaging and labelling systems, cameras to aid in visual inspection for release, in process and release testing and data collection, and end-to-end tracking and tracing of products. The utilization of these tools will increase accuracy, precision, speed and operational efficiencies, while decreasing manual errors and shortening the time to deliver vaccines to patients.  

    Artificial intelligence, machine learning and predictive insights can help life sciences manufacturers enhance manufacturing process operations and consolidate compliance-related manufacturing data contained in disparate systems across the enterprise into a single, visual interface. This includes data from laboratory information management, batch management, control, quality management, manufacturing execution and inventory systems.

    Utilization of single-use systems and components, real time process analytical testing and continuous manufacturing, present tremendous opportunities to reduce costs and to shorten supply chain durations significantly.

    Contract Pharma: At what stage of development can scale up efforts begin?

    Cynthia Pussinen: Commercial scale up to provide a vaccine to the public can begin once a GMP manufacturing facility and testing labs are fully compliant with regulations and ready to manufacture products using the final, locked down process. This process includes having defined and characterized critical quality attributes and process parameters that deliver a product which has been produced via a well-controlled and consistent manufacturing process. Teams that are fully trained in executing the manufacturing process, testing and release of the product are part of the process as well.

    Cynthia Pussinen is the vice president and general manager of Honeywell's pharmaceutical business, a strategic business unit within Honeywell’s Performance Materials and Technologies (PMT) division. Cynthia's prior experience includes 20 years with Pfizer in a variety of roles, including the head of strategic portfolio management, global head of supply chain logistics, and various other roles in research and development. Prior to Pfizer, she was president of Ipsen's U.S. subsidiary for about six years, which included technical operations and research and development activities. Most recently, Cynthia served as executive vice president of technical operations and supply chain for Actinium Pharmaceuticals, Inc.
    Suggested For You
    Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact
    GRAM, J&J Enter COVID-19 Vax Manufacturing Pact GRAM, J&J Enter COVID-19 Vax Manufacturing Pact
    J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax
    Hovione to Support Manufacture of Remdesivir for COVID-19 Hovione to Support Manufacture of Remdesivir for COVID-19
    ARCA Submits IND for AB201 in COVID-19 ARCA Submits IND for AB201 in COVID-19
    BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production
    Pharma Supply Chain Logistics & Potential COVID-19 Vaccines Pharma Supply Chain Logistics & Potential COVID-19 Vaccines
    Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies
    FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine
    Valneva Partners with UK Government for COVID-19 Vaccine Valneva Partners with UK Government for COVID-19 Vaccine
    Valneva, Dynavax Enter COVID-19 Vax Supply Pact  Valneva, Dynavax Enter COVID-19 Vax Supply Pact
    Novavax, Serum Institute of India Enter COVID-19 Vax Mfg. Pact Novavax, Serum Institute of India Enter COVID-19 Vax Mfg. Pact
    BioNTech to Receive German Federal Ministry Funding for COVID-19 Vax BioNTech to Receive German Federal Ministry Funding for COVID-19 Vax
    AstraZeneca Temporarily Halts COVID-19 Vax Trials of AZD1222 AstraZeneca Temporarily Halts COVID-19 Vax Trials of AZD1222
    iBio Advances COVID-19 Vaccine Candidate iBio Advances COVID-19 Vaccine Candidate

    Related Online Exclusives

    • Solid Dosage/Creams/Ointments
      Solid Dose Market Trends

      Solid Dose Market Trends

      A Q&A with Mark DaFonseca, chief business officer at CoreRx.
      Tim Wright, Editor, Contract Pharma 02.26.21

    • Drug Delivery
      Aerosol Delivery Devices Market

      Aerosol Delivery Devices Market

      Advantages over conventional drug delivery devices, rise in prevalence of COPD and asthma drive the growth of the global aerosol delivery devices market.
      Allied Market Research 02.16.21

    • Biologics, Proteins, Vaccines | Clinical Trials
      Inside a Vaccine Trial

      Inside a Vaccine Trial

      Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
      Kristin Brooks, Managing Editor 02.05.21


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      The Future of Vaccines and Biologics

      The Future of Vaccines and Biologics

      Dr. Linda Marbán of Capricor Therapeutics discusses the advances in responding to infectious diseases.
      Kristin Brooks, Managing Editor, Contract Pharma 02.04.21

    • Clinical Trials | Information Technology
      The State of Clinical Trial Technology

      The State of Clinical Trial Technology

      Blake Adams of Florence discusses key report findings and the clinical trial software used to support Pfizer’s global COVID-19 vaccine study.
      Kristin Brooks, Contract Pharma 01.26.21

    • Analytical Services | Laboratory Testing
      Improving Product Profitability

      Improving Product Profitability

      Using PAT/QbD/CM as tools to increase profitability of products.
      Emil Ciurczak, Contributing Editor 01.21.21


    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20


    • Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      CDMOs: Keeping up with Science & Technology

      CDMOs: Keeping up with Science & Technology

      Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.
      Kristin Brooks, Contract Pharma 11.12.20

    • Excipients
      Pharmaceutical Excipients Market Poised for Growth

      Pharmaceutical Excipients Market Poised for Growth

      The global pharmaceutical excipients market is estimated to surpass $11,944.6 million by 2027.
      Contract Pharma Staff 11.03.20

    • cGMP Manufacture | Fill/Finish | Scale-up/Technology Transfer
      Ramping Up COVID-19 Vaccine Fill and Finish Capacity

      Ramping Up COVID-19 Vaccine Fill and Finish Capacity

      As a partner to the U.S. Government, GRAM's newest facility was designed to increase large-scale fill and finish capacity with room to expand as demand grows.
      Kristin Brooks, Contract Pharma 11.03.20


    • Biologics, Proteins, Vaccines
      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      CMOs expand and ‘repurpose’ capacities.
      S Harachand, Contributing Editor 10.20.20

    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Drug Delivery
      Topical Drugs Poised for Growth

      Topical Drugs Poised for Growth

      The topical drug delivery market is projected to reach $129.8 billion by 2025 from $95.2 billion in 2020, at a CAGR of 6.4%.
      Contract Pharma Staff 10.12.20

    Trending
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • Catalent Acquires Delphi Genetics
    • Charles River Acquires CDMO Cognate BioServices
    • Spark Therapeutics Appoints CTO
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login